19056201 2025-01-01 2025-12-31 19056201 2025-01-01 2025-12-31 1 19056201 2025-01-01 2025-12-31 1 19056201 2025-01-01 2025-12-31 1 19056201 2025-01-01 2025-12-31 2 19056201 2025-01-01 2025-12-31 3 19056201 2024-01-01 2024-12-31 19056201 2025-12-31 19056201 2024-12-31 19056201 2024-01-01 d:ContributedCapitalMember 19056201 2024-01-01 d:RetainedEarningsMember 19056201 2024-01-01 2024-12-31 d:RetainedEarningsMember 19056201 2025-01-01 d:ContributedCapitalMember 19056201 2025-01-01 d:RetainedEarningsMember 19056201 2025-01-01 2025-12-31 d:RetainedEarningsMember 19056201 2025-12-31 d:ContributedCapitalMember 19056201 2025-12-31 d:RetainedEarningsMember iso4217:DKK xbrli:pure Årsrapport 30700228 EY Godkendt Revisionspartnerselskab Dirch Passers Allé 36 Postboks 250, 2000 Frederiksberg 2025-01-01 2025-12-31 2024-01-01 2024-12-31 19056201 PolyPeptide Laboratories A/S Herredsvejen 2 3400 Hillerød 1996-01-01 Hillerød 40366200 40366386 www.polypeptide.dk Danske Bank EY Godkendt Revisionspartnerselskab 30700228 Dirch Passers Allé 36 2000 Frederiksberg Danmark +45 73 23 30 00 2026-05-22 Raoul Bernhardt Regnskabsklasse B Revisionspåtegning Grundlag for konklusion Konklusion true true CaseWare Working Papers Bestyrelse og direktion har dags da­to be­hand­let og god­kendt års­rap­por­ten for PolyPeptide Laboratories A/S for regn­skabs­året 1. januar - 31. december 2025. Today, the Board of Directors and the Executive Board have discussed and approved the annual report of PolyPeptide Laboratories A/S for the financial year 1 January - 31 December 2025. Årsrapporten aflægges i over­ens­stem­mel­se med års­regn­skabs­lo­ven. The annual report is prepared in accordance with the Danish Financial Statements Act. Det er vores opfattelse, at årsregnskabet giver et retvisende billede af sel­ska­bets ak­ti­ver, pas­si­ver og finan­siel­le stil­ling pr. 31. december 2025 samt af re­sul­ta­tet af sel­ska­bets ak­ti­vi­te­ter for regn­skabs­året 1. januar - 31. december 2025. In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2025 and of the results of the Company's operations for the financial year 1 January - 31 December 2025. Det er endvidere vores opfattelse, at le­del­ses­be­ret­ningen inde­hol­der en ret­vi­sen­de rede­gø­rel­se for de forhold, beretningen omhandler. Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review. Årsrapporten indstilles til ge­ne­ral­for­sam­ling­ens god­ken­del­se. We recommend that the annual report be approved at the annual general meeting. Hillerød 2026-05-22 Raoul Bernhardt Juan José Gonzalez Casanova Christina Ellen Del Vecchio Raoul Bernhardt Til kapitalejeren i PolyPeptide Laboratories A/S To the shareholder of PolyPeptide Laboratories A/S Vi har revi­de­ret års­regn­ska­bet for PolyPeptide Laboratories A/S for regn­skabs­året 1. januar - 31. december 2025, der om­fat­ter re­sul­tat­op­gø­rel­se, ba­lan­ce, egen­ka­pi­tal­op­gø­rel­se og no­ter, her­un­der an­vendt regn­skabs­prak­sis. Års­regn­ska­bet ud­ar­bej­des efter års­regn­skabs­lo­ven. We have audited the financial statements of PolyPeptide Laboratories A/S for the financial year 1 January - 31 December 2025, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.Det er vores opfat­tel­se, at års­regn­ska­bet giver et ret­vi­sen­de bil­le­de af sel­ska­bets akti­ver, pas­si­ver og finan­si­el­le stil­ling pr. 31. december 2025 samt af resul­ta­tet af sel­ska­bets akti­vi­te­ter for regn­skabs­året 1. januar - 31. december 2025 i over­ens­stem­mel­se med års­regn­skabs­lo­ven. In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2025 and of the results of the Company's operations for the financial year 1 January - 31 December 2025 in accordance with the Danish Financial Statements Act. Vi har udført vores revision i overensstemmelse med inter­na­tio­na­le stan­dar­der om revi­sion og de yder­li­ge­re krav, der er gæl­den­de i Dan­mark. Vores ansvar iføl­ge dis­se stan­dar­der og krav er nær­me­re beskre­vet i revi­sions­på­teg­nin­gens afsnit "Revi­sors ansvar for revi­sio­nen af års­regn­ska­bet". Det er vores opfat­tel­se, at det opnå­ede revi­sions­be­vis er til­stræk­ke­ligt og eg­net som grund­lag for vores kon­klu­sion. We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.UafhængighedIndependenceVi er uaf­hæn­gi­ge af sel­ska­bet i over­ens­stem­mel­se med Inter­national Ethics Standards Board for Accountants' inter­na­tio­nale ret­nings­lin­jer for revi­so­rers eti­ske adfærd (IESBA Code) og de yder­lig­ere eti­ske krav, der er gæl­den­de i Dan­mark, lige­som vi har opfyldt vores øvri­ge etis­ke for­plig­tel­ser i hen­hold til dis­se krav og IESBA Code.We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. Ledelsen har ansvaret for udarbejdelsen af et års­regn­skab, der giver et ret­vi­sende billede i overens­stemmel­se med års­regn­skabs­lo­ven. Ledelsen har end­videre an­svaret for den in­ter­ne kontrol, som le­del­sen anser for nød­ven­dig for at udar­bejde et års­regn­skab uden væ­sent­lig fejl­in­for­ma­tion, uanset om denne skyldes besvigelser eller fejl. Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.Ved udarbejdelsen af årsregnskabet er ledelsen ansvarlig for at vurdere selskabets evne til at fortsætte driften; at oplyse om forhold vedrørende fortsat drift, hvor dette er relevant; samt at udar­bejde års­regn­ska­bet på grund­lag af regn­skabs­prin­cip­pet om fort­sat drift, med­mindre ledel­sen enten har til hen­sigt at lik­vi­dere sel­ska­bet, ind­stille drif­ten eller ikke har andet rea­lis­tisk alter­na­tiv end at gøre dette. In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Vores mål er at opnå høj grad af sikkerhed for, om årsregnskabet som hel­hed er uden væsent­lig fejl­in­for­ma­tion, uan­set om denne skyl­des besvi­gel­ser eller fejl, og at afgive en revi­si­ons­påt­eg­ning med en kon­klu­sion. Høj grad af sik­ker­hed er et højt niveau af sik­ker­hed, men er ikke en ga­ranti for, at en revi­sion, der udfø­res i over­ens­stem­mel­se med inter­na­tio­nale stan­dar­der om revision og de yder­li­gere krav, der er gæl­dende i Dan­mark, altid vil afdække væsent­lig fejl­in­for­ma­tion, når sådan fin­des. Fejl­in­for­ma­tio­ner kan opstå som følge af besvi­gel­ser eller fejl og kan betrag­tes som væsent­lige, hvis det med rime­lig­hed kan for­ven­tes, at de enkelt­vis eller sam­let har ind­fly­del­se på de øko­no­mi­ske be­slut­ninger, som regn­skabs­bru­gerne træf­fer på grund­lag af års­regn­skabet. Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.Som led i en revision, der udføres i over­ens­stem­mel­se med in­ter­na­tio­na­le stan­dar­der om re­vi­sion og de yder­li­ge­re krav, der er gæl­den­de i Dan­mark, fo­re­ta­ger vi fag­li­ge vur­de­rin­ger og op­ret­hol­der pro­fes­sio­nel skep­sis under re­vi­sio­nen. Her­ud­over: As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:Identificerer og vurderer vi risikoen for væsent­lig fejl­in­for­ma­tion i års­regn­ska­bet, uan­set om denne skyl­des besvi­gel­ser eller fejl, udfor­mer og udfø­rer revi­si­ons­hand­lin­ger som reak­tion på disse risici samt opnår revi­si­ons­be­vis, der er til­stræk­ke­ligt og egnet til at danne grund­lag for vores kon­klu­sion. Risi­koen for ikke at opdage væsent­lig fejl­in­for­ma­tion for­år­sa­get af besvi­gel­ser er høje­re end ved væsent­lig fejl­in­for­ma­tion for­år­sa­get af fejl, idet besvi­gel­ser kan om­fat­te sam­men­svær­gel­ser, doku­ment­falsk, bevid­ste ude­ladel­ser, vild­led­ning eller til­si­de­sæt­tel­se af intern kon­trol. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.Opnår vi for­stå­else af den inter­ne kon­trol med rele­vans for revi­sio­nen for at kunne udfor­me revi­si­ons­hand­lin­ger, der er pas­sen­de efter omstæn­dig­he­der­ne, men ikke for at kun­ne udtryk­ke en kon­klu­sion om effek­ti­vi­te­ten af sel­ska­bets inter­ne kon­trol. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.Tager vi stilling til, om den regn­skabs­prak­sis, som er anvendt af ledel­sen, er pas­sen­de, samt om de regn­skabs­mæs­sige skøn og til­knyt­te­de oplys­ninger, som ledel­sen har udar­bej­det, er rime­lige. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.Konkluderer vi, om le­del­sens udar­bej­del­se af års­regn­ska­bet på grund­lag af regn­skabs­prin­cip­pet om fort­sat drift er pas­sen­de, samt om der på grund­lag af det opnå­ede revi­si­ons­be­vis er væsent­lig usik­ker­hed for­bun­det med begi­ven­he­der eller for­hold, der kan skabe bety­de­lig tvivl om sel­ska­bets evne til at fort­sætte drif­ten. Hvis vi kon­klu­de­rer, at der er en væsent­lig usik­ker­hed, skal vi i vores revi­si­ons­på­teg­ning gøre opmærk­som på oplys­ninger her­om i års­regn­ska­bet eller, hvis sådan­ne oplys­nin­ger ikke er til­stræk­ke­li­ge, modi­fi­ce­re vores kon­klu­sion. Vores kon­klu­sion er base­ret på det revi­si­ons­be­vis, der er opnå­et frem til da­to­en for vores revi­si­ons­på­teg­ning. Frem­ti­di­ge begi­ven­he­der eller for­hold kan dog med­føre, at sel­ska­bet ikke læn­ge­re kan fort­sæt­te drif­ten. Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.Tager vi stilling til den sam­le­de præ­sen­ta­tion, struk­tur og ind­hold af års­regn­ska­bet, her­under note­oplys­ning­erne, samt om års­regn­ska­bet afspej­ler de under­lig­gen­de trans­ak­ti­oner og begi­ven­he­der på en sådan måde, at der gives et ret­vi­sen­de bil­le­de her­af. Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.Vi kom­mu­ni­ke­rer med den øver­ste ledel­se om bl.a. det plan­lag­te omfang og den tids­mæs­sige pla­ce­ring af revi­sio­nen samt bety­de­li­ge revi­si­ons­mæs­si­ge obser­va­tio­ner, her­under even­tu­el­le bety­de­li­ge mang­ler i intern kon­trol, som vi iden­ti­fi­ce­rer under revi­sio­nen. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. Ledelsen er ansvarlig for ledelsesberetningen. Management is responsible for the Management's review.Vores konklusion om års­regn­ska­bet omfat­ter ikke ledel­ses­be­ret­ning­en, og vi ud­tryk­ker ingen form for kon­klu­sion med sik­ker­hed om ledel­ses­be­ret­ning­en. Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.I tilknytning til vores revision af års­regn­ska­bet er det vores ansvar at læse ledel­ses­be­ret­ning­en og i den for­bin­del­se over­ve­je, om ledel­ses­be­ret­ning­en er væsent­ligt inkon­si­stent med års­regn­ska­bet eller vores viden opnå­et ved revi­sio­nen eller på anden måde sy­nes at inde­hol­de væsent­lig fejl­in­for­ma­tion. In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.Vores ansvar er derudover at overveje, om ledel­ses­be­ret­ning­en inde­hol­der kræ­ve­de oplys­nin­ger i hen­hold til års­regn­skabs­lo­ven. Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.Baseret på det udfør­te arbej­de er det vores opfat­tel­se, at ledel­ses­be­ret­ning­en er i over­ens­stem­mel­se med års­regn­ska­bet og er udar­bej­det i over­ens­stem­mel­se med års­regn­skabs­lo­vens krav. Vi har ikke fun­det væsent­lig fejl­in­for­ma­tion i ledel­ses­be­ret­ning­en. Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review. København 2026-05-22 Jacob Thøgersen statsaut. revisor State Authorised Public Accountant mne49102 Selskabet har været uden aktiviteter siden udgangen af 2016. The Company has been without activities since the end of 2016. Selskabets resultat­opgørelse for 2025 ud­vi­ser et over­skud på 2.632 t.kr. mod et over­skud på 7.060 t.kr. sidste år, og sel­ska­bets balance pr. 31. december 2025 udviser en egen­kapital på 75.499 t.kr. The income statement for 2025 shows a profit of DKK 2,632 thousand against a profit of DKK 7,060 thousand last year, and the balance sheet at 31 December 2025 shows equity of DKK 75,499 thousand. Der er ikke efter balancedagen indtruffet begivenheder af væsentlig betydning for virksomhedens finansielle stilling. No significant events have occurred subsequent to the financial year-end. 50000 36000 -50000 -36000 3424000 4639000 0 366000 3374000 4237000 742000 -2823000 2632000 7060000 2632000 7060000 73439000 69994000 2080000 2823000 75519000 72817000 0 71000 75519000 72888000 75519000 72888000 20000000 20000000 55499000 52867000 75499000 72867000 20000 21000 20000 21000 20000 21000 75519000 72888000 20000000 45807000 7060000 20000000 52867000 2632000 20000000 55499000 Årsrapporten for PolyPeptide Laboratories A/S for 2025 er aflagt i over­ens­stem­mel­se med års­regn­skabs­lo­vens be­stem­mel­ser for klas­se Bvirk­som­he­der med tilvalg af visse bestemmelser for klasse C. The annual report of PolyPeptide Laboratories A/S for 2025 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities. Årsregnskabet er aflagt efter samme regnskabspraksis som sidste år. The annual accounts have been prepared in accordance with the same accounting practice as last year. Præsentationsvaluta Reporting currencyÅrsregnskabet er aflagt i danske kroner (DKK'000). The financial statements are presented in Danish kroner (DKK'000). Trans­ak­tio­ner i frem­med valu­ta omreg­nes ved før­ste ind­reg­ning til trans­ak­ti­ons­da­gens kurs. Valu­ta­kurs­dif­fe­ren­cer, der opstår mel­lem trans­ak­ti­ons­da­gens kurs og kur­sen på beta­lings­da­gen, ind­regnes i resul­tat­op­gø­rel­sen som en finan­si­el post. On initial recognition, transactions denominated in foreign currencies are translated at the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.Til­go­de­ha­ven­der, gæld og andre mone­tæ­re pos­ter i frem­med valu­ta om­reg­nes til balan­ce­da­gens valu­ta­kurs. For­skel­len mel­lem balan­ce­da­gens kurs og kur­sen på tids­punk­tet for til­go­de­ha­ven­dets eller gælds­for­plig­tel­sens opstå­en eller ind­reg­ning i senes­te års­regn­skab ind­reg­nes i resul­tat­op­gø­rel­sen under finan­si­el­le ind­tæg­ter og omkost­nin­ger. Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rate at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the most recent financial statements is recognised in the income statement as financial income or financial expenses. I administrationsomkostninger indregnes om­kost­ning­er, der er afholdt i året til ledelse og administration af selskabet, herunder omkost­ninger til ad­mini­stra­tivt personale, ledelsen, kontorlokaler og kontor­om­kost­ninger samt af­skrivninger på aktiver, som be­nyt­tes i admi­ni­strationen. Administrative expenses include expenses incurred in the year for purposes of managing and administering the Company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes. Finansielle indtægter og omkostninger indreg­nes i re­sultatopgørelsen med de beløb, der ved­rører regn­skabs­året. Fi­nan­siel­le pos­ter om­fat­ter ren­te­ind­tæg­ter og om­kostninger samt til­læg og godt­gø­rel­se un­der acon­to­skat­te­ord­nin­gen m.v. Financial income and expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest income and expenses as well as allowances and surcharges under the advance-payment-of-tax scheme, etc. Skat af årets resultat omfatter aktuel skat af årets for­ventede skattepligtige indkomst og årets re­gu­le­ring af ud­skudt skat. Årets skat indregnes i resul­tat­op­gø­rel­sen med den del, der kan henføres til årets re­sul­tat, og i egen­kapi­talen med den del, som kan hen­fø­res til trans­aktioner indregnet i egenkapi­talen. Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity. Virksomheden har valgt IAS 39 som fortolk­nings­bidrag for nedskrivninger af finansielle til­gode­ha­ven­der. The Company has chosen IAS 39 as interpretation for impairment write-down of financial receivables.Tilgodehavender måles til amortiseret kostpris. Receivables are measured at amortised cost.Der fore­ta­ges ned­skriv­ning til imø­de­gå­el­se af tab, hvor der vur­de­res at være ind­truf­fet en objek­tiv indi­ka­ti­on på, at et til­go­de­ha­ven­de eller en por­te­føl­je af til­go­de­ha­ven­der er vær­di­for­rin­get. Hvis der fore­lig­ger en objek­tiv indi­ka­ti­on på, at et indi­vi­du­elt til­go­de­ha­ven­de er vær­di­for­rin­get, fore­ta­ges ned­skriv­ning på indi­vi­du­elt nive­au. An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.Tilgodehavender, hvor der ikke foreligger en objek­tiv indi­ka­ti­on på vær­di­for­rin­gel­se på indi­vi­du­elt niveau, vur­de­res på por­te­føl­je­ni­veau for objek­tiv indi­ka­ti­on for vær­di­for­rin­gel­se. Por­te­føl­je­rne base­res pri­mært på debi­to­rer­nes hjem­sted og kre­dit­vur­de­ring i over­ens­stem­mel­se med virk­som­he­dens risi­ko­sty­rings­po­li­tik. De objek­ti­ve indi­ka­to­rer, som anven­des for por­te­føl­jer, er fast­sat base­ret på histo­ris­ke tabs­er­fa­rin­ger. Receivables in respect of which there is no objective evidence of individual impairment are tested for objective evidence of impairment on a portfolio basis. The portfolios are primarily based on the debtors' domicile and credit ratings in line with the Company's risk management policy. The objective evidence applied to portfolios is determined based on historical loss experience.Ned­skriv­nin­ger opgø­res som for­skel­len mel­lem den regn­skabs­mæs­sige vær­di af til­go­de­ha­ven­der og nutids­vær­di­en af de for­ven­te­de pen­ge­strøm­me, her­un­der rea­li­sa­ti­ons­vær­di af even­tu­el­le mod­tag­ne sik­ker­heds­stil­lel­ser. Som dis­kon­te­rings­sats anven­des den effek­ti­ve ren­te for det enkel­te til­go­de­ha­ven­de eller por­te­føl­je. Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate. Likvider omfatter likvide beholdninger og kortfristede værdipapirer, som uden hindring kan omsættes til likvide beholdninger, og hvorpå der kun er ubetydelige risici for værdiændringer. Indestående eller gæld på koncernens cash pool-ordning anses som følge af ordningens karakter ikke som likvide beholdgninger, men indgår i regnskabsposten tilgodehavende til tilknyttede virksomheder. Cash comprise cash and short term securities which are readily convertible into cash and subject only to minor risks of changes in value. Balances or liabilities under the Group’s cash pool arrangement are, due to the nature of the arrangement, not considered cash and cash equivalents, but are included in the financial statement line item receivables to related parties. Virksomheden har valgt IAS 39 som for­tolk­nings­bidrag til indregning og måling af gælds­for­plig­tel­ser. The Company has chosen IAS 39 as interpretation for liabilities.Finan­si­el­le gælds­for­plig­tel­ser ind­reg­nes ved lån­op­ta­gel­se til det mod­tag­ne pro­ve­nu efter fra­drag af afhold­te trans­ak­ti­ons­om­kost­nin­ger. I efter­føl­gen­de peri­oder måles de finan­si­el­le for­plig­tel­ser til amor­ti­se­ret kost­pris, sva­ren­de til den kapi­ta­li­se­re­de vær­di ved anven­del­se af den effek­ti­ve ren­te, så for­skel­len mel­lem pro­ve­nu­et og den nomi­nel­le vær­di ind­reg­nes i resul­tat­op­gø­rel­sen over låne­pe­ri­oden. I finan­si­el­le for­plig­tel­ser ind­reg­nes til­li­ge den kapi­ta­li­se­re­de rest­lea­sing­for­plig­tel­se på finan­si­el­le lea­sing­kon­trak­ter. Financial liabilities are recognised at the date of borrowing at the net proceeds received less transaction costs paid. On subsequent recognition, financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest rate. Accordingly, the difference between the proceeds and the nominal value is recognised in the income statement over the term of the loan. Financial liabilities also include the capitalised residual lease liability in respect of finance leases.Andre gældsforpligtelser måles til netto­rea­li­sa­tions­værdien. Other liabilities are measured at net realisable value. 3423000 4636000 1000 3000 742000 -2823000 0 0 Virksomheden har ingen eventualforpligtelser pr. 31. december 2025. The company has no commitments at 31 December 2025. Virksomheden har ikke stillet pant eller anden sikker­hed i aktiver pr. 31. december 2025. No assets were pledged as collateral or otherwise charged at 31 December 2025. Oplysning om koncernregnskaberInformation about consolidated financial statements ModervirksomhedParentHjemstedDomicileRekvirering af modervirk­som­hedens kon­cern­regnskabRequisitioning of the parent company's consolidated financial statements PolyPeptide Group AGNeuhofstrasse 24, 6340 Baar, SwitzerlandPå selskabets adresse / At the Company's address EjerforholdOwnership Følgende kapitalejere er noteret i virksomhedens ejerbog som ejende minimum 5 % af stemmerne eller minimum 5 % af aktiekapitalen:The following shareholders are registered in the Company's register of shareholders as holding minimum 5% of the votes or minimum 5% of the share capital: NavnNameBopæl/HjemstedDomicile PolyPeptide Laboratories Holding (PPL) ABSverige